In an in vitro study, psoralen significantly suppressed T helper type 2 (Th2) cytokines such as IL-4, IL-5 and IL-13 and therefore regarded as a critical component of PF for its in vivo therapeutic effects on airway hyperresponsiveness and inflammation of asthma [43]. The gene discussed is IL5; the disease is airway hyperresponsiveness.